These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 27084342)

  • 1. The "Pain wave": P‑wave oversensing in subcutaneous ICD.
    Kattih B; Duncker D; König T; Hohmann S; Oswald H; Veltmann C
    Herzschrittmacherther Elektrophysiol; 2016 Jun; 27(2):151-3. PubMed ID: 27084342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter investigation of an implantable cardioverter-defibrillator algorithm to detect oversensing.
    Welte N; Strik M; Eschalier R; Mondoly P; Defaye P; Frontera A; Ritter P; Haïssaguerre M; Ploux S; Koneru J; Ellenbogen KA; Bordachar P
    Heart Rhythm; 2017 Jul; 14(7):1008-1015. PubMed ID: 28323174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oversensing issues leading to device extraction: When subcutaneous implantable cardioverter-defibrillator reached a dead-end.
    Noel A; Ploux S; Bulliard S; Strik M; Haeberlin A; Welte N; Marchand H; Klotz N; Ritter P; Haïssaguerre M; Bordachar P
    Heart Rhythm; 2020 Jan; 17(1):66-74. PubMed ID: 31295585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-wave oversensing by an implantable cardioverter defibrillator after successful ablation of idiopathic ventricular fibrillation.
    Strohmer B; Schernthaner C; Pichler M
    Pacing Clin Electrophysiol; 2006 Apr; 29(4):431-5. PubMed ID: 16650276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous Implantable Cardioverter Defibrillator Lead Repositioning for Preventing Inappropriate Shocks Due to Myopotential Oversensing in a Post-Fulminant Myocarditis Patient.
    Sasaki T; Nakamura K; Naito S
    Int Heart J; 2019 Mar; 60(2):466-469. PubMed ID: 30745542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Causes of ventricular oversensing in implantable cardioverter-defibrillators: implications for diagnosis of lead fracture.
    Gunderson BD; Swerdlow CD; Wilcox JM; Hayman JE; Ousdigian KT; Ellenbogen KA
    Heart Rhythm; 2010 May; 7(5):626-33. PubMed ID: 20184977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of an electrocardiographic screening tool to determine candidacy for a subcutaneous implantable cardioverter-defibrillator.
    Groh CA; Sharma S; Pelchovitz DJ; Bhave PD; Rhyner J; Verma N; Arora R; Chicos AB; Kim SS; Lin AC; Passman RS; Knight BP
    Heart Rhythm; 2014 Aug; 11(8):1361-6. PubMed ID: 24755323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-time "real-life" performance of the subcutaneous ICD in patients with electrical heart disease or idiopathic ventricular fibrillation.
    Frommeyer G; Dechering DG; Kochhäuser S; Bettin M; Köbe J; Eckardt L; Reinke F
    J Interv Card Electrophysiol; 2016 Nov; 47(2):185-188. PubMed ID: 27217031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy.
    Maurizi N; Olivotto I; Olde Nordkamp LR; Baldini K; Fumagalli C; Brouwer TF; Knops RE; Cecchi F
    Heart Rhythm; 2016 Feb; 13(2):457-63. PubMed ID: 26362577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new algorithm to reduce inappropriate therapy in the S-ICD system.
    Brisben AJ; Burke MC; Knight BP; Hahn SJ; Herrmann KL; Allavatam V; Mahajan D; Sanghera R; Gold MR
    J Cardiovasc Electrophysiol; 2015 Apr; 26(4):417-423. PubMed ID: 25581303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific indications and clinical outcome in patients with subcutaneous implantable cardioverter-defibrillator (ICD) - A nationwide multicentre registry.
    Sponder M; Khazen C; Dichtl W; Fiedler L; Mörtl D; Teubl A; Steinwender C; Martinek M; Nürnberg M; Dalos D; Kastner J; Schukro C
    Eur J Intern Med; 2018 Feb; 48():64-68. PubMed ID: 28978409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
    Przybylski A; Małecka L; Pytkowski M; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Ruzyłło W; Szwed H
    Kardiol Pol; 2005 Oct; 63(4):391-7; discussion 398. PubMed ID: 16273479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inappropriate subcutaneous implantable cardioverter-defibrillator shocks due to T-wave oversensing can be prevented: implications for management.
    Kooiman KM; Knops RE; Olde Nordkamp L; Wilde AA; de Groot JR
    Heart Rhythm; 2014 Mar; 11(3):426-34. PubMed ID: 24321235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [An unusual series of complications in therapy with implantable cardioverter-defibrillator].
    Peters W; Hopp H; Bauer WR; Kowallik P; Meesmann M
    Z Kardiol; 1995 Apr; 84(4):296-300. PubMed ID: 7785302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of myopotential induction in subcutaneous implantable cardioverter-defibrillator patients: Is the oversensing issue really solved?
    van den Bruck JH; Sultan A; Plenge T; Seuthe K; Mödder T; Iliadis C; Stern D; Blankenheim T; Steven D; Lüker J
    Heart Rhythm; 2019 Oct; 16(10):1523-1530. PubMed ID: 31048064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inappropriate discharges from an intravenous implantable cardioverter defibrillator due to T-wave oversensing.
    Washizuka T; Chinushi M; Kasai H; Watanabe H; Tagawa M; Hosaka Y; Abe A; Aizawa Y
    Jpn Circ J; 2001 Jul; 65(7):685-7. PubMed ID: 11446507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
    Roses-Noguer F; Jarman JW; Clague JR; Till J
    Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential role of home monitoring to reduce inappropriate shocks in implantable cardioverter-defibrillator patients due to lead failure.
    Spencker S; Coban N; Koch L; Schirdewan A; Müller D
    Europace; 2009 Apr; 11(4):483-8. PubMed ID: 19103654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator.
    Gold MR; Weiss R; Theuns DA; Smith W; Leon A; Knight BP; Carter N; Husby M; Burke MC
    Heart Rhythm; 2014 Aug; 11(8):1352-8. PubMed ID: 24732366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.